Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines

被引:49
|
作者
Jiang, Ying [2 ]
Tong, Dandan [3 ]
Lou, Ge [2 ]
Zhang, Ying [2 ]
Geng, Jingshu [1 ]
机构
[1] Harbin Med Coll, Affiliated Hosp 3, Dept Pathol, Harbin 150086, Peoples R China
[2] Harbin Med Coll, Affiliated Hosp 2, Dept Pathol, Harbin 150086, Peoples R China
[3] Harbin Med Coll, Basic Med Coll, Dept Pathol, Harbin 150086, Peoples R China
关键词
breast cancer; methylation; RUNX3; gene; prognosis;
D O I
10.1159/000132385
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Runt-related transcription factor 3 (RUNX3) is a novel tumor suppressor gene that is frequently silenced by promoter hypermethylation in gastric cancer. In this study, we aimed to analyze the methylation status of the RUNX3 promoter in breast cancer and to evaluate the relationship between RUNX3 expression and breast carcinogenesis and prognosis. Methods: RT-PCR and Western blot were applied on 5 breast cancer cell lines, the human normal breast cell line Hs578Bst and 30 pairs of breast cancer and their matching normal breast tissues to detect mRNA and protein expression of the RUNX3 gene. Methylation-specific PCR was employed to detect the methylation status of the RUNX3 promoter. Immunohistochemical study was performed to analyze RUNX3 protein expression in 88 breast cancer tissues and 40 breast fibroadenomas. Results: The expression of RUNX3 mRNA and protein were negative in 3 breast cancer cell lines (T47D, MCF7 and SKBR3) as analyzed by RT-PCR and Western blotting. Hypermethylation of the RUNX3 promotor was identified in the T47D and MCF7 cell lines, but was not detected in SKBR3. Western blot analysis showed that the RUNX3 protein of 44 kDa was detected in 15 of 30 (50%) breast cancers. However, RUNX3 protein was detected in all normal breast tissues. Methylation was detected in 13 of the 15 tissues (86.67%) that did not express RUNX3 protein, but was never detected in any surrounding normal tissues. Immunohistochemistry results revealed that the positive rate of RUNX3 protein expression in breast cancer (35.23%) was much lower than that in breast fibroadenoma (85%). RUNX3 expression was correlated with tumor infiltration, clinical stage, lymph node metastasis and the expression of estrogen and progesterone receptor (p < 0.05), but was not related to age, tumor types and pathological grade (p < 0.05). The survival rate of the patients with RUNX3-positive expression was higher than that with RUNX3-negative expression (p < 0.05). Conclusions: The expression of RUNX3 gene is decreased in breast cancer. The RUNX3 gene may play an important role in the carcinogenesis of breast cancer. The mechanism of its inactivation may be hypermethylation of the promoter. With the increased progression of breast cancer, the expression of RUNX3 protein tends to decrease. The expression of RUNX3 protein has a definite value in judging prognosis in breast cancer. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:244 / 251
页数:8
相关论文
共 50 条
  • [21] Expression and clinicopathological significance of FSIP1 in breast cancer
    Zhang, Hao
    Luo, Minna
    Jin, Zining
    Wang, Dan
    Sun, Ming
    Zhao, Xinhan
    Zhao, Zuowei
    Lei, Haixin
    Li, Man
    Liu, Caigang
    ONCOTARGET, 2015, 6 (12) : 10658 - 10666
  • [22] Gene Expression of Kallikreins in Breast Cancer Cell Lines
    Watrowski, Rafal
    Castillo-Tong, Dan Cacsire
    Obermayr, Eva
    Zeillinger, Robert
    ANTICANCER RESEARCH, 2020, 40 (05) : 2487 - 2495
  • [23] TrkB Promotes Breast Cancer Metastasis via Suppression of Runx3 and Keap1 Expression
    Kim, Min Soo
    Lee, Won Sung
    Jin, Wook
    MOLECULES AND CELLS, 2016, 39 (03) : 258 - 265
  • [24] RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer
    Liu, Hui
    Yan, Zhantao
    Yin, Qianqian
    Cao, Kai
    Wei, Yu
    Rodriguez-Canales, Jaime
    Ma, Dongshen
    Wu, Yongping
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2018, 66 (10) : 709 - 721
  • [25] RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer
    Bai, Jin
    Yong, Hong-Mei
    Chen, Fei-Fei
    Song, Wen-Bo
    Li, Chen
    Liu, Hui
    Zheng, Jun-Nian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (11) : 1813 - 1823
  • [26] Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer
    Han, Lin-Lin
    Hou, Lin
    Zhou, Ming-Jin
    Ma, Zhong-liang
    Lin, Dong-Liang
    Wu, Li
    Ge, Yin-lin
    JOURNAL OF BIOMEDICAL SCIENCE, 2013, 20
  • [27] Clinicopathological Significance of Mesothelin Expression in Invasive Breast Cancer
    Wang, L.
    Niu, Z.
    Zhang, L.
    Liu, X.
    Wang, X.
    Li, F.
    Wang, Y.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (03) : 909 - 916
  • [28] Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell Lines
    Ari, Ferda
    Napieralski, Rudolf
    Ulukaya, Engin
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2013, 38 (02): : 154 - 162
  • [29] Clinicopathological significance of β-tubulin isotype III gene expression in breast cancer patients
    He, Qingqing
    Peng, Bo
    Zhuang, Dayong
    Xiao, Lei
    Zheng, Luming
    Fan, Ziyi
    Zhu, Jian
    Xu, Benmei
    Xu, Cheng
    Zhao, Jiangman
    Wu, Liming
    Zhou, Peng
    Hou, Lei
    Yu, Fang
    Zhao, Guowei
    CANCER BIOMARKERS, 2015, 15 (06) : 823 - 831
  • [30] Lack of RUNX3 inactivation in columnar cell lesions of breast
    Subramaniam, Manish Mani
    Chan, Jason Yongsheng
    Omar, Mohd Feroz Mohd
    Ito, Kosei
    Ito, Yoshiaki
    Yeoh, Khay Guan
    Salto-Tellez, Manuel
    Putti, Thomas Choudary
    HISTOPATHOLOGY, 2010, 57 (04) : 555 - 563